Product Description
Japanese Encephalitis purified inactivated vaccine (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00604708)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Intercell USA
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Encephalitis, Japanese
Phase 3: Encephalitis, Japanese|Encephalitis, Viral|Encephalomyelitis|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | N/A |
Not yet recruiting |
Diabetes Complications|Diabetes, Gestational|Pregnancy Outcomes |
2021-12-14 |
|
ND01 | N/A |
Not yet recruiting |
Tobacco Use Disorder |
2019-09-02 |
|
2009-015595-10 | P3 |
Completed |
Encephalitis, Japanese |
2013-08-09 |
|
IC51-322 | P3 |
Completed |
Encephalitis, Japanese |
2013-08-01 |